On May 4, 2020, Cerus announced FDA regulatory approval for manufacture of INTERCEPT plasma with a new, alternative plastic disposable kit. The INTERCEPT Blood System for plasma is designed to pathogen reduce a broad spectrum of viruses, bacteria, protozoa, and contaminating donor leukocytes in plasma components to reduce the risk of transfusion transmitted infections.